• Product name
    Anti-MELK antibody [EPR3981]
    See all MELK primary antibodies
  • Description
    Rabbit monoclonal [EPR3981] to MELK
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC,IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human MELK (N terminal). The exact sequence is proprietary.

  • Positive control
    • WB: K562, 293T, and Jurkat cell lysates.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents



Our Abpromise guarantee covers the use of ab108529 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 75 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC,IHC-P or IP.
  • Target

    • Function
      Phosphorylates ZNF622 and may contribute to its redirection to the nucleus. May be involved in the inhibition of spliceosome assembly during mitosis.
    • Tissue specificity
      Expressed in placenta, kidney, thymus, testis, ovary and intestine.
    • Sequence similarities
      Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. SNF1 subfamily.
      Contains 1 KA1 (kinase-associated) domain.
      Contains 1 protein kinase domain.
    • Post-translational
      Autophosphorylated. Thr-478 phosphorylation during mitosis promotes interaction with PPP1R8.
    • Cellular localization
    • Information by UniProt
    • Database links
    • Alternative names
      • AI327312 antibody
      • hMELK antibody
      • HPK 38 antibody
      • hPK38 antibody
      • KIAA0175 antibody
      • Likely ortholog of maternal embryonic leucine zipper kinase antibody
      • Maternal embryonic leucine zipper kinase antibody
      • MELK antibody
      • MELK_HUMAN antibody
      • mKIAA0175 antibody
      • MPK38 antibody
      • OTTHUMP00000021377 antibody
      • OTTHUMP00000046113 antibody
      • pEg3 kinase antibody
      • Protein kinase Eg3 antibody
      • Protein kinase PK38 antibody
      • RP23 382O11.1 antibody
      • Tyrosine protein kinase MELK antibody
      see all

    Anti-MELK antibody [EPR3981] images

    • Predicted band size : 75 kDa

      Lane 1: Wild-type HAP1 cell lysate (20 µg)
      Lane 2: MELK knockout HAP1 cell lysate (20 µg)
      Lane 3: HeLa cell lysate (20 µg)
      Lane 4: HCT116 cell lysate (20 µg)

      Lanes 1 - 4: Merged signal (red and green). Green - ab108529 observed at 75 kDa. Red - loading control, ab8226, observed at 42 kDa.

      ab108529 was shown to recognize MELK when MELK knockout samples were used, along with additional cross-reactive bands. Wild-type and MELK knockout samples were subjected to SDS-PAGE. ab108529 and ab8226 (loading control to beta Actin) were both diluted 1/1000 and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.

    • All lanes : Anti-MELK antibody [EPR3981] (ab108529) at 1/1000 dilution

      Lane 1 : K562 cell lysate
      Lane 2 : 293T cell lysate
      Lane 3 : Jurkat cell lysate

      Lysates/proteins at 10 µg per lane.

      HRP-labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size : 75 kDa

    References for Anti-MELK antibody [EPR3981] (ab108529)

    This product has been referenced in:
    • Lin A  et al. CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. Elife 6:N/A (2017). Read more (PubMed: 28337968) »
    • Wang Y  et al. Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proc Natl Acad Sci U S A 113:9810-5 (2016). Read more (PubMed: 27528663) »

    See all 4 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab108529.
    Please use the links above to contact us or submit feedback about this product.


    Sign up